Eli Lilly and Company (NYSE:LLY) Stock Falls 1.1% - Here's Why

Key Points

• Eli Lilly shares fell 1.1% to about $1,242.76 in midday trading, with volume 34% below the average.
• The company reported strong recent results, including adjusted EPS of $8.38 versus the $6.40 consensus and 47.7% year-over-year revenue growth. Investors also see potential catalysts from the Foundayo obesity treatment, positive pediatric Omvoh data and pipeline investments.
• Despite a “Moderate Buy” consensus and a $1,313.43 average price target, concerns remain over Lilly’s elevated valuation, dependence on obesity drugs, competition with Novo Nordisk and an insulin-pricing lawsuit.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price traded down 1.1% during mid-day trading on Monday. The stock traded as low as $1,239.10 and last traded at $1,242.7580. 1,947,631 shares traded hands during trading, a decline of 34% from the average daily volume of 2,949,663 shares. The stock had previously closed at $1,257.03.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo could gain market share: Bank of America expects Lilly’s oral GLP-1 treatment, Foundayo, to continue gaining share over the next 12 months. Separately, European regulators recommended approval, potentially expanding Lilly’s obesity-drug reach and supporting sales growth. Foundayo market-share article European Foundayo approval article
• Positive Sentiment: Positive Omvoh pediatric data: Omvoh met the primary endpoint in a Phase 3 pediatric ulcerative-colitis study. Among induction responders, 50% achieved clinical remission at one year, with Lilly planning regulatory submissions for a potential label expansion. Omvoh pediatric trial article
• Positive Sentiment: Pipeline and technology investments: Lilly will present new oncology data at the ESMO Congress and agreed to pay Metis TechBio up to $1.1 billion for AI-enabled drug-delivery technology. These developments could broaden Lilly’s future product base beyond obesity medicines. Metis TechBio deal article
• Neutral Sentiment: Analyst and investor debate: RBC reiterated a Buy view, while multiple analyses questioned whether Lilly’s rapid growth, improving margins and upcoming medicines—including retatrutide—can support its elevated valuation.
• Negative Sentiment: Competition and concentration risks: Investors are monitoring a potential price war with Novo Nordisk and Lilly’s heavy dependence on its obesity portfolio, which could pressure pricing or magnify the impact of disappointing product results.
• Negative Sentiment: Insulin-price lawsuit: A Pennsylvania complaint alleges Lilly and other manufacturers inflated insulin prices by more than 1,000%. The allegations could create legal costs, reputational damage and additional pricing scrutiny, although no liability has been established. Lilly insulin lawsuit article

Analyst Ratings Changes

Several equities research analysts recently weighed in on LLY shares. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a "buy" rating in a research note on Tuesday, September 15th. Sanford C. Bernstein boosted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,313.43.

Eli Lilly and Company Price Performance

The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock's 50 day simple moving average is $1,180.08 and its two-hundred day simple moving average is $1,109.55. The stock has a market cap of $1.17 trillion, a price-to-earnings ratio of 41.70, a P/E/G ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the firm posted $6.31 EPS. The business's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts forecast that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Large investors have recently modified their holdings of the stock. James Hambro & Partners LLP boosted its stake in Eli Lilly and Company by 38.3% in the 3rd quarter. James Hambro & Partners LLP now owns 1,831 shares of the company's stock valued at $2,123,000 after purchasing an additional 507 shares during the period. Richards Merrill & Peterson Inc. grew its holdings in Eli Lilly and Company by 8.6% in the 3rd quarter. Richards Merrill & Peterson Inc. now owns 1,255 shares of the company's stock valued at $1,452,000 after buying an additional 99 shares in the last quarter. New Wave Wealth Advisors LLC increased its position in Eli Lilly and Company by 3.5% during the 3rd quarter. New Wave Wealth Advisors LLC now owns 2,511 shares of the company's stock worth $2,929,000 after buying an additional 84 shares during the period. Talbot Financial LLC lifted its holdings in shares of Eli Lilly and Company by 0.3% during the third quarter. Talbot Financial LLC now owns 37,225 shares of the company's stock worth $43,072,000 after buying an additional 119 shares in the last quarter. Finally, Cornell Pochily Investment Advisors Inc. boosted its position in shares of Eli Lilly and Company by 6.4% in the third quarter. Cornell Pochily Investment Advisors Inc. now owns 1,818 shares of the company's stock valued at $2,103,000 after acquiring an additional 110 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.